TREATMENT OF CHILDHOOD SOCIAL PHOBIA

描述（改编自申请人的摘要）：社交恐惧症影响3-5% 儿童的患病率随着年龄的增长而上升。青少年社交恐惧症 公开演讲，在公共场合阅读或写作，参加聚会，互动 与权威人士，使用公共厕所和非正式互动， 他人临床症状包括头痛或胃痛，恐慌， 回避、普遍焦虑、烦躁不安、孤独，范围非常有限 社会关系。在极端情况下，学校拒绝或其他行为 问题的结果。缺乏社会发展所需的社会技能 很常见其他疾病经常同时发生，最常见的是广泛性焦虑症 分离焦虑症和特殊恐惧症。很少 治疗研究，这种衰弱，慢性，和高度流行的疾病。 最近的研究结果表明，一种新的心理社会治疗（社会效益 儿童治疗; SET-C）对8-11岁的儿童有效， 情绪困扰和社会功能改善。治疗效果已经 保持长达6个月。因为社交恐惧症的流行 随着年龄的增长，至少在青春期，青少年的治疗是 needed.此处提议的研究将是一项两地研究， 将SET-C扩展到更大的样本，并将年龄范围扩展到15岁。因为 现有数据表明氟西汀是一种有前途的药理学药物， 在一项双盲随机化研究中，将SET-C与氟西汀进行比较。 安慰剂对照设计。氟西汀尚未与安慰剂进行比较， 控制设计使用儿童社交恐惧症的代表性样本。 因此，该研究将允许使用一种新的方法继续评估SET-C的疗效。 扩大了年龄范围，并与氟西汀进行了比较。此外，研究将 提供氟西汀与安慰剂相比的疗效数据。最后， 将在1年随访期内监测治疗的持久性。的 样本将足够大，以提供临床置信度 研究结果的意义，并进行初步研究， 治疗临床医生的预测和调节。类似地， 将获得百忧解的疗效。

DESCRIPTION (Adapted from the Applicant's Abstract): Social phobia affects 3-5% of children, and prevalence rises with age. Youth with social phobia fear public speaking, reading or writing in public, going to parties, interacting with authority figures, using public restrooms and interacting informally with others. Clinical correlates include headaches or stomachaches, panic, avoidance, general anxiety, dysphoria, loneliness, and a very restricted range of social relationships. In extreme cases, school refusal or other behavior problems result. Deficiencies in social skills necessary for social development are common. Other disorders frequently co-occur, most often generalized anxiety disorder, separation anxiety disorder, and specific phobia. There are few treatment studies of this debilitating, chronic, and highly prevalent disorder. Recent findings indicate a new psychosocial treatment (Social Effectiveness Therapy for Children; SET-C) is efficacious for ages 8-11, resulting in reduced emotional distress and improved social functioning. Treatment effects have been maintained for up to 6 months. Because the prevalence of social phobia increases with age at least through adolescence, treatments for adolescents are needed. The study proposed here will be a two-site study extending the study of SET-C to a larger sample, and extending the age range to age 15. Because available data suggest that fluoxetine is a promising pharmacological treatment, SET-C will be compared to fluoxetine in a double-blind randomized placebo control design. Fluoxetine has yet to be compared to pill placebo in a controlled design using a representative sample of childhood social phobics. Thus, the study will allow continued evaluation of SET-C's efficacy using an expanded age range, and comparing it to fluoxetine. Furthermore, the study will provide data on the efficacy of fluoxetine compared to pill placebo. Finally, durability of treatment will be monitored over a 1-year follow-up period. The sample will be sufficiently large to provide confidence in the clinical meaningfulness of the findings and to conduct initial studies examining predictors and moderators of treatment clinicians. Similarly, critical data on the efficacy of fluoxetine will be available.